Fairfax, VANCT06022029Now EnrollingIRB Ready

Triple Negative Breast Cancer Clinical Trial in Fairfax, VA

Access cutting-edge triple negative breast cancer treatment through this clinical trial at a research site in Fairfax. Study-provided care at no cost to qualified participants.

Sponsored by OncoNano Medicine, Inc.

Quick Self-Assessment

See if you qualify for this Fairfax location

Preparing your pre-screening questions…

Expert Care in Fairfax

Access triple negative breast cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related triple negative breast cancer treatment provided free

Apply for This Fairfax Location

Check if you qualify for this triple negative breast cancer clinical trial in Fairfax, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fairfax

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fairfax site if eligible
  4. 4Begin participation

About This Triple Negative Breast Cancer Study in Fairfax

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.

Sponsor: OncoNano Medicine, Inc.

Who Can Participate

Inclusion Criteria

Ability to understand and willingness to sign written informed consent before performance of any study procedures
Age ≥ 18 years
Participants with solid tumors or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or recurrent and progressing since last antitumor therapy, and for which no alternative standard therapy exists.
Participants must have a minimum of one injectable and measurable lesion.
Participants with prior Hepatitis B or C are eligible if they have adequate liver function
Participants with human immunodeficiency virus (HIV) are eligible if on established HAART for a minimum of 4 weeks prior to enrollment, have an HIV viral load \<400 copies/mL, and have CD4+ T-cell (CD4+) counts ≥ 350 cells/uL
Adequate bone marrow function:
Adequate liver function

Exclusion Criteria

Patients will be excluded from this study if they meet any of the following criteria (Part 1a and Part 1b).
Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has completed curative therapy.
Major surgery within 4 weeks before the first dose of study drug.
Brain metastases that are untreated or in the posterior fossa or involve the meninges. Participants with stable or previously treated progressing brain metastases (except in the posterior fossa or involving the meninges) may be permitted in a case-by-case basis at the Sponsor's discretion.
Prolongation of corrected QT (QTc) interval to \>470 millisecond (ms) for males and females when electrolytes balance is normal.
Females who are breastfeeding or pregnant at screening or baseline
Females of childbearing potential that refuse to use a highly effective method of contraception.
Has uncontrolled or poorly controlled hypertension as defined by a sustained BP \> 9. Has received prior investigational therapy within 5 half-lives of the agent or 4 weeks before the first administration of study drug, whichever is shorter.
Has had any major cardiovascular event within 6 months prior to study drug 10. Has known hypersensitivity to any component in the formulation of ONM-501
Has an active infection requiring systemic treatment
Is participating in another therapeutic clinical trial Additional Exclusion Criteria for ONM-501 in Combination with cemiplimab (Part 1b)
Has known hypersensitivity to any component in the formulation of cemiplimab
Has any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (\>10 mg daily prednisone equivalent)
Has a condition requiring systemic treatment with corticosteroids

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fairfax?

Yes, this clinical trial (NCT06022029) has an active research site in Fairfax, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Triple Negative Breast Cancer Treatment Options in Fairfax, VA

If you're searching for triple negative breast cancer treatment options in Fairfax, VA, this clinical trial (NCT06022029) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fairfax research site is actively enrolling participants for this clinical trial. You'll receive care from experienced triple negative breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all triple negative breast cancer clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Fairfax, VA

See all breast cancer clinical trials recruiting in Fairfax — not just this study.

Browse Breast Cancer Trials in Fairfax →

Browse More Trials by Condition

Breast Cancer TrialsTriple Negative Breast Cancer TrialsAnkylosing Spondylitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Fairfax?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fairfax, VA